Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 SLN | Healthcare | $19.83 | 586.52K | $1.23B | -7.26 | ― | Hold |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SLN | Silence Therapeutics | 19.83 | 13.00 | 190.34% |
| Name | Price | % Change | |
|---|---|---|---|
| SLN | $19.83 | +190.34% |
Cash and cash equivalents were $247.7 million as of September 30, 2026. This includes $201.3 million in gross proceeds from an upsized public offering announced on August 11, 2026. Published
H.C. Wainwright analyst Patrick Trucchio downgraded Silence Therapeutics (SLN) to Neutral from Buy with a price target of $20, down from $75, to reflect the proposed acquisition by Merck KGaA.
Jefferies downgraded Silence Therapeutics (SLN) to Hold from Buy with a price target of $20, down from $35, after Merck KGaA (MKGAY) announced plans to acquire the company for $20
William Blair analyst Myles Minter downgraded Silence Therapeutics (SLN) to Market Perform from Outperform after the company announced it has entered into an agreement with Merck KGaA (MKGAY) for $20
Silence Therapeutics stock soared 125.69% on Monday following a $1.3 billion acquisition offer from Merck KGaA.
Chardan downgraded Silence Therapeutics (SLN) to Neutral from Buy with a price target of $20, down from $27, after the company entered into an agreement to be acquired by Merck
Silence Therapeutics (SLN) has entered into a definitive agreement with Merck KGaA (MKGAY), Darmstadt, Germany, pursuant to which Merck KGaA, Darmstadt, Germany has agreed to acquire Silence in an all-cash
08:01 EDT Merck KGaA (MKGAY) to acquire Silence Therapeutics (SLN) for $20 per ADS in cash Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
Merck KGaA (MKGAY) announced its entry into a definitive agreement to acquire Silence Therapeutics plc (SLN). The purchase price of $20 per ADS in cash, with each ADS representing three
Jefferies, Morgan Stanley, Cantor Fitzgerald and William Blair acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| SLN | Mar 17, 2027TBA | $1.23B | $-0.09 | $87.00K | -0.01 | -7.26 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
